CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target

References

• Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207–14.
   PubMed Web of Science ®Google Scholar
• Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, et al. Expression of CA-IX is associated with advanced stage tumours and poor survival in oral squamous cell carcinoma patients. J Oral Pathol Med 2012;41:667–74.
   PubMed Web of Science ®Google Scholar
• Chen J, Rocken C, Hoffmann J, et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005;54:920–7.
   PubMed Web of Science ®Google Scholar
• Jung JH, Im S, Jung ES, Kang CS. Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer. Int J Med Sci 2013;10:1217–23.
   PubMed Web of Science ®Google Scholar
• Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 2010;14:18–29.
   PubMed Web of Science ®Google Scholar
• Birner P, Jesch B, Friedrich J, et al. Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 2011;18:3330–7.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kato H, Inose T, et al. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008;99:1468–75.
   PubMed Web of Science ®Google Scholar
• Ameis HM, Drenckhan A, Freytag M, et al. Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma. J Enzyme Inhib Med Chem 2016;31:404–9.
   PubMed Web of Science ®Google Scholar
• Ameis HM, Drenckhan A, Freytag M, et al. Influence of hypoxia-dependent factors on the progression of neuroblastoma. Pediatr Surg Int 2016;32:187–92.
   PubMed Web of Science ®Google Scholar
• Driessen A, Landuyt W, Pastorekova S, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334–40.
   PubMed Web of Science ®Google Scholar
• Dungwa JV, Hunt LP, Ramani P. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Hum Pathol 2012;43:1651–60.
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Giannoni E, Taddei ML, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013;12:1791–801.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumour hypoxia: suppression of breast tumour growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76.
   PubMed Web of Science ®Google Scholar
• Schweiger T, Kollmann D, Nikolowsky C, et al. Carbonic anhydrase IX is associated with early pulmonary spreading of primary colorectal carcinoma and tobacco smoking. Eur J Cardio-Thorac Surg 2014;46:92–9.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene 2013;32:5210–9.
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013;381:400–12.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Whitney-Miller C. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol 2011;19:506–8.
   PubMedGoogle Scholar
• Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr Opin Oncol 2013;25:417–24.
   PubMed Web of Science ®Google Scholar
• Gros SJ, Kurschat N, Dohrmann T, et al. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 2010;9:2037–45.
   PubMed Web of Science ®Google Scholar
• Gros SJ, Kurschat N, Drenckhan A, et al. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PloS One 2012;7:e47287.
   PubMed Web of Science ®Google Scholar
• Scheunemann P, Izbicki JR, Pantel K. Tumourigenic potential of apparently tumour-free lymph nodes. N Engl J Med 1999;340:1687.
   PubMed Web of Science ®Google Scholar
• Gros SJ, Dohrmann T, Peldschus K, et al. Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. Int J Cancer 2010;126:2671–81.
   PubMed Web of Science ®Google Scholar
• Drenckhan A, Grob T, Dupree A, et al. Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. Langenbecks Arch Surg 2014;399:879–88.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003;200:375–82.
   PubMed Web of Science ®Google Scholar
• Wittekind C, Hutter RVP, Klimpfinger M, Sobin LH. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumours. 5th ed. 2005.
   Google Scholar
• Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 2002;76:1488–95.
   PubMed Web of Science ®Google Scholar
• Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther 2008;16:698–706.
   PubMed Web of Science ®Google Scholar
• Drenckhan A, Kurschat N, Dohrmann T, et al. Effective inhibition of metastases and primary tumour growth with CTCE-9908 in esophageal cancer. J Surg Res 2013;182:250–6.
   PubMed Web of Science ®Google Scholar
• Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res 2007;13:1947–9.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumour cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358–68.
   PubMed Web of Science ®Google Scholar
• Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007;85:1301–7.
   PubMed Web of Science ®Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumour progression. Oncologist 2004;9:10–7.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000;88:1474–80.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp Physiol 2006;91:803–6.
   PubMed Web of Science ®Google Scholar
• Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumour physiology through gene expression patterns. Oncogene 2003;22:5907–14.
   PubMed Web of Science ®Google Scholar
• Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumours. J Natl Cancer Inst 2001;93:1337–43.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumour-associated carbonic anhydrases. Cancer Res 2000;60:7075–83.
   PubMed Web of Science ®Google Scholar
• Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp 2006;272:15–25.
   PubMedGoogle Scholar
• Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumour progression. Crit Rev Biochem Mol Biol 2000;35:71–103.
   PubMed Web of Science ®Google Scholar
• Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004;3:164–7.
   PubMed Web of Science ®Google Scholar
• Zhou J, Schmid T, Schnitzer S, Brune B. Tumour hypoxia and cancer progression. Cancer Lett 2006;237:10–21.
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Whelan KA, Schwab LP, Karakashev SV, et al. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumour growth and anoikis resistance. J Biol Chem 2013;288:15865–77.
   PubMed Web of Science ®Google Scholar
• Kyotani Y, Ota H, Itaya-Hironaka A, et al. Intermittent hypoxia induces the proliferation of rat vascular smooth muscle cell with the increases in epidermal growth factor family and erbB2 receptor. Exp Cell Res 2013;319:3042–50.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Obradovic MM, Hoffmann M, et al. Early dissemination seeds metastasis in breast cancer. Nature 2016. doi:10.1038/nature20785
   Web of Science ®Google Scholar
• Tu TC, Nagano M, Yamashita T, et al. A chemokine receptor, CXCR4, which is regulated by hypoxia-inducible factor 2alpha, is crucial for functional endothelial progenitor cells migration to ischemic tissue and wound repair. Stem Cells Dev 2016;25:266–76.
   PubMed Web of Science ®Google Scholar
• Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391–402.
   PubMed Web of Science ®Google Scholar
• Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307–11.
   PubMed Web of Science ®Google Scholar
• Valsecchi R, Coltella N, Belloni D, et al. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumour microenvironmenttumour. Blood 2016;127:1987–97.
   PubMed Web of Science ®Google Scholar
• Arvidsson Y, Bergstrom A, Arvidsson L, et al. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr-Relat Cancer 2010;17:303–16.
   PubMed Web of Science ®Google Scholar
• Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer 2010;10:225.
   PubMed Web of Science ®Google Scholar
• Guan G, Zhang Y, Lu Y, et al. The HIF-1α/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells. Cancer Lett 2015;357:254–64.
   PubMed Web of Science ®Google Scholar
• Guo M, Cai C, Zhao G, et al. Hypoxia promotes migration and induces CXCR4 expression via HIF-1α activation in human osteosarcoma. PloS One 2014;9:e90518.
   PubMed Web of Science ®Google Scholar
• Zagzag D, Lukyanov Y, Lan L, et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006;86:1221–32.
   PubMed Web of Science ®Google Scholar
• Wang X, Li C, Chen Y, et al. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem Biophys Res Commun 2008;371:283–8.
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Gao X, Tsuruoka S, et al. SDF1 induction by acidosis from principal cells regulates intercalated cell subtype distribution. J Clin Invest 2015;125:4365–74.
   PubMed Web of Science ®Google Scholar
• Abe Y, Uchinami H, Kudoh K, et al. Liver epithelial cells proliferate under hypoxia and protect the liver from ischemic injury via expression of HIF-1 alpha target genes. Surgery 2012;152:869–78.
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, et al. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int 2011;107:118–25.
   PubMed Web of Science ®Google Scholar
• Oosterwijk-Wakka JC, de Weijert MC, Franssen GM, et al. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC. Neoplasia 2015;17:215–24.
   PubMed Web of Science ®Google Scholar
• Jomrich G, Jesch B, Birner P, et al. Stromal expression of carbonic anhydrase IX in esophageal cancer. Clin Transl Oncol 2014;16:966–72.
   PubMed Web of Science ®Google Scholar
• Huber AR, Tan D, Sun J, et al. High expression of carbonic anhydrase IX is significantly associated with glandular lesions in gastroesophageal junction and with tumourigenesis markers BMI1, MCM4 and MCM7. BMC Gastroenterol 2015;15:80.
   PubMed Web of Science ®Google Scholar
• Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 2009;92:423–8.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Huizing FJ, Hoeben BAW, Franssen G, et al. Preclinical validation of (111)In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts. Radiother Oncol 2017;124:521–5.
   PubMed Web of Science ®Google Scholar
• Stillebroer AB, Franssen GM, Mulders PF, et al. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother Radiopharm 2013;28:510–5.
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Stillebroer AB, Rijpkema M, et al. Optical imaging of renal cell carcinoma with anti-carbonic anhydrase IX monoclonal antibody girentuximab. J Nucl Med 2014;55:1035–40.
   PubMed Web of Science ®Google Scholar
• van Dijk J, Uemura H, Beniers AJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumour necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994;56:262–8.
   PubMed Web of Science ®Google Scholar
• Muselaers CHJ, Oosterwijk E, Bos DL, et al. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model. Mol Imag 2014;13:1–7.
   PubMed Web of Science ®Google Scholar